{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:38:18Z","timestamp":1792165098689,"version":"4.4.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002889","name":"Foundation for Prader-Willi Research","doi-asserted-by":"publisher","award":["Foundation for Prader-Willi Research"],"award-info":[{"award-number":["Foundation for Prader-Willi Research"]}],"id":[{"id":"10.13039\/100002889","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Soleno Therapeutics","award":["Soleno Therapeutics"],"award-info":[{"award-number":["Soleno Therapeutics"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurodevelop Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Prader-Willi syndrome (PWS) is a rare neurobehavioral-metabolic disease caused by the lack of paternally expressed genes in the chromosome 15q11-q13 region, characterized by hypotonia, neurocognitive problems, behavioral difficulties, endocrinopathies, and hyperphagia resulting in severe obesity if energy intake is not controlled. Diazoxide choline extended-release (DCCR) tablets have previously been evaluated for their effects on hyperphagia and other behavioral complications of people with PWS in a Phase 3 placebo-controlled study of participants with PWS, age 4 and older with hyperphagia (C601) and in an open label extension study, C602.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>To better understand the longer-term impact of DCCR, a cohort from PATH for PWS, a natural history study that enrolled participants with PWS age 5 and older, who met the C601 age, weight and baseline hyperphagia inclusion criteria and had 2 hyperphagia assessments\u2009\u2265\u20096 months apart, were compared to the C601\/C602 cohort. Hyperphagia was measured using the Hyperphagia Questionnaire for Clinical Trials (HQ-CT, range 0\u201336). The primary analysis used observed values with no explicit imputation of missing data. A sensitivity analysis was conducted in which all missing HQ-CT assessments in the C601\/C602 cohort were assigned the highest possible value (36), representing the worst-case scenario. Other behavioral changes were assessed using the Prader-Willi Syndrome Profile questionnaire (PWSP).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Relative to the PATH for PWS natural history study cohort, the DCCR-treated C601\/C602 cohort showed significant improvements in HQ-CT score at 26 weeks (LSmean [SE] -8.3 [0.75] vs. -2.5 [0.43], <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and 52 weeks (LSmean [SE] -9.2 [0.77] vs. -3.4 [0.47], <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The comparison between the cohorts remained significant in the worst-case imputation sensitivity analysis. There were also significant improvements in all domains of the PWSP at 26 weeks (all <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and 52 weeks (all <jats:italic>p<\/jats:italic>\u2009\u2264\u20090.003) for C601\/C602 participants compared to the PATH for PWS participants.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Long-term administration of DCCR to people with PWS resulted in changes in hyperphagia and other behavioral complications of PWS that are distinct from the natural history of the syndrome as exemplified by the cohort from PATH for PWS. The combined effects of administration of DCCR should reduce the burden of the syndrome on the patient, caregivers and their families, and thereby may benefit people with PWS and their families.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial Registration<\/jats:title>\n                <jats:p>Clinical study C601 was originally registered on ClinicalTrials.gov on February 22, 2018 (NCT03440814). Clinical study C602 was originally registered on ClinicalTrials.gov on October 22, 2018 (NCT03714373). PATH for PWS was originally registered on ClinicalTrials.gov on October 24, 2018 (NCT03718416).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s11689-024-09536-x","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T10:02:51Z","timestamp":1714125771000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Behavioral changes in patients with Prader-Willi syndrome receiving diazoxide choline extended-release tablets compared to the PATH for PWS natural history study"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6783-8703","authenticated-orcid":false,"given":"Theresa V.","family":"Strong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn E.","family":"McCandless","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelien","family":"Gevers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack A.","family":"Yanovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Matesevac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Bohonowych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaila","family":"Ballal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil M.","family":"Cowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish","family":"Bhatnagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,26]]},"reference":[{"key":"9536_CR1","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/ajmg.a.36845","volume":"167A","author":"T Lionti","year":"2015","unstructured":"Lionti T, Reid SM, White SM, Rowell MM. A population-based profile of 160 australians with Prader-Willi syndrome: trends in diagnosis, birth prevalence and birth characteristics. Am J Med Genet A. 2015;167A:371\u20138. https:\/\/doi.org\/10.1002\/ajmg.a.36845.","journal-title":"Am J Med Genet A"},{"key":"9536_CR2","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/s10038-018-0451-x","volume":"63","author":"MA Gillentine","year":"2018","unstructured":"Gillentine MA, Lupo PJ, Stankiewicz P, Schaaf CP. An estimation of the prevalence of genomic disorders using chromosomal microarray data. J Hum Genet. 2018;63:795\u2013801. https:\/\/doi.org\/10.1038\/s10038-018-0451-x.","journal-title":"J Hum Genet"},{"key":"9536_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2174\/1573396315666190716120925","volume":"15","author":"MG Butler","year":"2019","unstructured":"Butler MG, Miller JL, Forster JL. Prader-Willi syndrome \u2013 clinical genetics, diagnosis and treatment approaches: an update. Curr Pediatr Rev. 2019;15:207\u201344. https:\/\/doi.org\/10.2174\/1573396315666190716120925.","journal-title":"Curr Pediatr Rev"},{"key":"9536_CR4","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1002\/ajmg.a.33951","volume":"155A","author":"JL Miller","year":"2011","unstructured":"Miller JL, Lynn CH, Driscoll DC, Goldstone AP, Gold J-A, Kimonis V, Dykens E, Butler MG, Shuster JJ, Driscoll DJ. Nutritional phases in Prader-Willi syndrome. Am J Med Genet Part A. 2011;155A:1040\u20139. https:\/\/doi.org\/10.1002\/ajmg.a.33951.","journal-title":"Am J Med Genet Part A"},{"key":"9536_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1542\/peds.2010-2820","volume":"127","author":"SE McCandless","year":"2011","unstructured":"McCandless SE, Committee on Genetics American Academy of Pediatrics. Clinical report-health supervision for children with prader-Willi syndrome. Pediatrics. 2011;127:195\u2013204. https:\/\/doi.org\/10.1542\/peds.2010-2820.","journal-title":"Pediatrics"},{"key":"9536_CR6","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/gim.2016.178","volume":"19","author":"MG Butler","year":"2017","unstructured":"Butler MG, Manzardo AM, Heinemann J, Loker C, Loker J. Causes of death in Prader-Willi syndrome: Prader-Willi Association (USA) 40-year mortality survey. Genet Med. 2017;19:635\u201342. https:\/\/doi.org\/10.1038\/gim.2016.178.","journal-title":"Genet Med"},{"key":"9536_CR7","doi-asserted-by":"publisher","first-page":"104379","DOI":"10.1016\/j.ejmg.2021.104379","volume":"65","author":"SA Bellis","year":"2022","unstructured":"Bellis SA, Kuhn I, Adams S, Mullarkey L, Holland A. The consequences of hyperphagia in people with prader-Willi syndrome: a systematic review of studies of morbidity and mortality. Eur J Med Genet. 2022;65:104379. https:\/\/doi.org\/10.1016\/j.ejmg.2021.104379.","journal-title":"Eur J Med Genet"},{"key":"9536_CR8","unstructured":"Summary of the Impact of PWS on Individuals and Their Families and Views on Treatments: Results of an International Online Survey. Available online: https:\/\/www.fpwr.org\/pws-patient-voices. Accessed April 4, 2023."},{"key":"9536_CR9","doi-asserted-by":"publisher","unstructured":"Tsai J-H, Scheimann AO, McCandless SE, Strong TV, Bridges JFP. Caregiver priorities for endpoints to evaluate treatments for Prader-Willi syndrome: a best-worst scaling. J Med Econ. 2018;21:1230\u20131237. doi: https:\/\/doi.org\/10.1080\/13696998.2018.1528980.","DOI":"10.1080\/13696998.2018.1528980"},{"key":"9536_CR10","doi-asserted-by":"publisher","unstructured":"Castellano JM, Ariza-Jimenez AB, Tena-Sempere M. New avenues for pharmacological management of hyperphagia and associated behavioral disorders in Prader-Willi syndrome. J Clin Endocrinol Metab 2023; 108(9):e895-e896. doi: https:\/\/doi.org\/10.1210\/clinem\/dgad131.","DOI":"10.1210\/clinem\/dgad131"},{"key":"9536_CR11","doi-asserted-by":"publisher","unstructured":"Kishore P, Boucai L, Zhang K, Li W, Koppaka S, Kehlenbrink S, Schiwek A, Sterson YB, Mehta D, Bursheh S, Su Y, Gutierrez-Juarez R, Muzumdar R, Schwartz GJ, Hawkins M. Activation of KATP channels suppresses glucose production in humans. J Clin Invest. 2011;121:4916\u20134920. doi: https:\/\/doi.org\/10.1172\/JCI58035.","DOI":"10.1172\/JCI58035"},{"key":"9536_CR12","doi-asserted-by":"publisher","unstructured":"Cowen N, Bhatnagar A. The potential role of activating the ATP-sensitive potassium channel in the treatment of hyperphagic obesity. Genes (Basel). 2020;11:450. doi: https:\/\/doi.org\/10.3390\/genes11040450.","DOI":"10.3390\/genes11040450"},{"key":"9536_CR13","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1210\/clinem\/dgad014","volume":"108","author":"JL Miller","year":"2022","unstructured":"Miller JL, Gevers E, Bridges N, Yanovski JA, Salehi P, Obrynba KS, Felner EI, Bird LM, Shoemaker AH, Angulo M, Butler MG, Stevenson D, Abuzzahab J, Barrett T, Lah M, Littlejohn E, Mathew V, Cowen NM, Bhatnagar A. Diazoxide choline extended-release tablet in people with Prader-Willi syndrome: A double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2023; 108 [7]:1676\u20131685 doi: https:\/\/doi.org\/10.1210\/clinem\/dgad014.","journal-title":"J Clin Endocrinol Metab"},{"key":"9536_CR14","doi-asserted-by":"publisher","unstructured":"Miller JL, Gevers E, Bridges N, Yanovski JA, Salehi P, Obrynba KS, Felner EI, Bird LM, Shoemaker AH, Angulo M, Butler MG, Stevenson D, Goldstone AP, Wilding J, Lah M, Guftar Shaikh M, Littlejohn E, Abuzzahab MJ, Fleischman A, Hirano P, Yen K, Cowen NM, Bhatnagar A, C601\/C602 Investigators. Diazoxide choline extended-release tablet in people with Prader-Willi syndrome: results from long-term open-label study. Obesity (Silver Spring) 2024; 32 [2]252\u2013261. Doi: https:\/\/doi.org\/10.1002\/oby.23928.","DOI":"10.1002\/oby.23928"},{"key":"9536_CR15","doi-asserted-by":"publisher","unstructured":"Fehnel S, Brown TM, Nelson L, Chen A, Roof E, Kim DD, Dykens EM. Development of the hyperphagia questionnaire for use in Prader-Willi syndrome clinical trials. Value in Health. 2015;18 [3]:PA25. Doi: https:\/\/doi.org\/10.1016\/j.vl.2015.03.154.","DOI":"10.1016\/j.vl.2015.03.154"},{"key":"9536_CR16","doi-asserted-by":"publisher","unstructured":"Matesevac L, Vrana-Diaz CJ, Bohonowych JE, Schwartz L, Strong TV. Analysis of Hyperphagia Questionnaire for Clinical Trials (HQ-CT) scores in typically developing individuals and those with Prader-Willi syndrome. Sci Rep. 13:20573, 2023. doi: https:\/\/doi.org\/10.1038\/s41598-023-48024-5.","DOI":"10.1038\/s41598-023-48024-5"},{"key":"9536_CR17","doi-asserted-by":"publisher","unstructured":"McCandless SE, Yanovski JA, Miller J, Fu C, Bird LM, Salehi P, Chan CL, Stafford D, Abuzzahab MJ, Viskochil D, Barlow SE, Angulo M, Myers SE, Whitman BY, Styne D, Roof E, Dykens EM, Scheimann AO, Malloy J, Zhuang D, Taylor K, Hughes TE, Kim DD, Butler MG. Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 19:1751\u20131761, 2017. doi: https:\/\/doi.org\/10.1111\/dom.13021.","DOI":"10.1111\/dom.13021"},{"key":"9536_CR18","doi-asserted-by":"publisher","unstructured":"Dykens EM, Roof E, Hunt-Hawkins H. The Prader-Willi syndrome Profile: validation of a new measure of behavioral and emotional problems in Prader-Willi syndrome. Orphanet J Rare Dis 2024; 19 [1]:83. doi: https:\/\/doi.org\/10.1186\/s13023-024-03045-9.","DOI":"10.1186\/s13023-024-03045-9"}],"container-title":["Journal of Neurodevelopmental Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11689-024-09536-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11689-024-09536-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11689-024-09536-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T10:02:58Z","timestamp":1714125778000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneurodevdisorders.biomedcentral.com\/articles\/10.1186\/s11689-024-09536-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,26]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["9536"],"URL":"https:\/\/doi.org\/10.1186\/s11689-024-09536-x","relation":{},"ISSN":["1866-1955"],"issn-type":[{"value":"1866-1955","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,26]]},"assertion":[{"value":"30 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Clinical studies C601 and C602 were reviewed and approved by the WCG Institutional Review Board, and the PATH for PWS natural history study was reviewed and approved by Hummingbird Institutional Review Board, and subsequently overseen by the North Star Review Board. Subjects or their parents\/guardians provided informed consent and, as appropriate, assent, prior to being enrolled in each study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SB, PH, KY, NC and AB are employed by Soleno Therapeutics. The institution of JLM, SEM, EG, and JAY received funding from Soleno to support the conduct of the clinical trial. EG reports receipt of lecturing and consulting fees from Soleno. JAY reports grant support from Soleno Therapeutics and from Rhythm Pharmaceuticals for obesity-related projects, and material support for research from Hikma Pharmaceuticals and Versanis-Bio and is supported by the Intramural Research Program of the <i>Eunice Kennedy Shriver<\/i> National Institute of Child Health and Human Development, National Institutes of Health, ZIAHD000641. TVS, JB and LM are employed by FPWR.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"22"}}